TrialBritish journal of haematology2022

Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase-2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts.

Claire N Harrison et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.